MedicalSystem Biotechnology Co Ltd operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MedicalSystem Biotechnology Co Ltd with three other
companies in this sector in China:
Shanghai Kehua Bio-Engineering Co., Ltd.
sales of 1.99 billion Chinese Renmimbi [US$289.44 million]
of which 57%
was Agent product),
Guangzhou Wondfo Biotech Co Ltd
(1.65 billion Chinese Renmimbi [US$239.97 million]
of which 73%
was Diagnostic Products), and
Maccura Biotechnology Co Ltd
(2.66 billion Chinese Renmimbi [US$386.92 million]
MedicalSystem Biotechnology Co Ltd reported sales of 3.14 billion Chinese Renmimbi (US$455.94 million)
December of 2018.
increase of 73.7%
versus 2017, when the company's sales were 1.81 billion Chinese Renmimbi.
Sales at MedicalSystem Biotechnology Co Ltd have increased during each of the previous five years
(and since 2013, sales have increased a total of 626%).
Sales of Medical Diagnostic Services saw an increase
89.7% in 2018, from
243.62 million Chinese Renmimbi to 462.25 million Chinese Renmimbi.
Not all segments of MedicalSystem Biotechnology Co Ltd experienced an increase in sales in 2018:
sales of Others fell 32.4% to 45.40 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).